Although HPV-positive oropharyngeal cancer is now recognized to be a distinct entity, it is important to recognize that the AJCC staging system, similar to most clinical trials, have considered p16-positivity to be equivalent to HPV-positivity. This evidence concerns the gene CDKN2A and oropharynx cancer.